Display options
Cite
Willenheimer R. Angiotensin receptor blockers in heart failure after the ELITE II trial. Curr Control Trials Cardiovasc Med. 2000;1(2):79-82doi: 10.1186/cvm-1-2-079.
Willenheimer, R. (2000). Angiotensin receptor blockers in heart failure after the ELITE II trial. Current controlled trials in cardiovascular medicine, 1(2), 79-82. https://doi.org/10.1186/cvm-1-2-079
Willenheimer, Ronnie. "Angiotensin receptor blockers in heart failure after the ELITE II trial." Current controlled trials in cardiovascular medicine vol. 1,2 (2000): 79-82. doi: https://doi.org/10.1186/cvm-1-2-079
Willenheimer R. Angiotensin receptor blockers in heart failure after the ELITE II trial. Curr Control Trials Cardiovasc Med. 2000;1(2):79-82. doi: 10.1186/cvm-1-2-079. PMID: 11714415; PMCID: PMC59604.
Copy Download .nbib Format: NLM
Share it on

Curr Control Trials Cardiovasc Med. 2000;1(2):79-82. doi: 10.1186/cvm-1-2-079.

Angiotensin receptor blockers in heart failure after the ELITE II trial.

Current controlled trials in cardiovascular medicine

Ronnie Willenheimer

Affiliations

  1. University Hospital Malmö, Malmö, Sweden. [email protected]

PMID: 11714415 PMCID: PMC59604 DOI: 10.1186/cvm-1-2-079

Abstract

Specific blockers of the angiotensin type1 receptor, angiotensin receptor blockers (ARBs), have been introduced as an alternative to angiotensin-converting enzyme inhibitors (ACEi) for the treatment of heart failure. In comparison with ACEi, ARBs are better tolerated and have similar effects on haemodynamics, neurohormones and exercise capacity. Early studies have suggested that ARBs might have a superior effect on mortality. However, the first outcome trial, ELITE II (Losartan Heart Failure Survival Study), did not show any significant difference between losartan and captopril in terms of mortality or morbidity. This commentary outlines the role of ARBs in the treatment of heart failure.

References

  1. J Cardiovasc Pharmacol. 1982 Nov-Dec;4(6):966-72 - PubMed
  2. Circulation. 1995 Feb 1;91(3):691-7 - PubMed
  3. Int J Cardiol. 1998 Aug;65(3):239-46 - PubMed
  4. N Engl J Med. 2000 Jan 20;342(3):145-53 - PubMed
  5. J Card Fail. 1999 Sep;5(3):276-82 - PubMed
  6. Lancet. 2000 May 6;355(9215):1575-81 - PubMed
  7. Am J Cardiol. 1994 Mar 1;73(7):488-93 - PubMed
  8. JAMA. 1995 May 10;273(18):1450-6 - PubMed
  9. Am J Hypertens. 2000 Apr;13(4 Pt 1):418-26 - PubMed
  10. Am Heart J. 2000 Apr;139(4):609-17 - PubMed
  11. J Am Coll Cardiol. 1999 Apr;33(5):1174-81 - PubMed
  12. Cardiology. 1999;91 Suppl 1:19-22 - PubMed
  13. Circulation. 1993 Oct;88(4 Pt 1):1602-9 - PubMed
  14. Circulation. 1999 Nov 30;100(22):2224-30 - PubMed
  15. J Am Coll Cardiol. 2000 Jun;35(7):1801-7 - PubMed
  16. Eur Heart J. 2000 Jan;21(1):53-7 - PubMed
  17. Circulation. 1999 Sep 7;100(10):1056-64 - PubMed
  18. Lancet. 1997 Mar 15;349(9054):747-52 - PubMed
  19. Eur Heart J. 1999 Jul;20(14):997-1008 - PubMed
  20. J Am Coll Cardiol. 1997 Oct;30(4):983-91 - PubMed
  21. Am Heart J. 1999 Nov;138(5 Pt 1):843-8 - PubMed
  22. Lancet. 2000 May 6;355(9215):1582-7 - PubMed
  23. Am J Cardiol. 2000 Jan 15;85(2):187-92 - PubMed
  24. J Clin Pharm Ther. 1998 Apr;23 (2):133-6 - PubMed
  25. Int J Cardiol. 1997 Mar;59(1):7-10 - PubMed
  26. J Am Coll Cardiol. 1995 Aug;26(2):438-45 - PubMed

Publication Types